RT Journal Article
SR Electronic
T1 COVID-19 severity is associated with immunopathology and multi-organ damage
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.19.20134379
DO 10.1101/2020.06.19.20134379
A1 Yan-Mei Chen
A1 Yuanting Zheng
A1 Ying Yu
A1 Yunzhi Wang
A1 Qingxia Huang
A1 Feng Qian
A1 Lei Sun
A1 Zhi-Gang Song
A1 Ziyin Chen
A1 Jinwen Feng
A1 Yanpeng An
A1 Jingcheng Yang
A1 Zhenqiang Su
A1 Shanyue Sun
A1 Fahui Dai
A1 Qinsheng Chen
A1 Qinwei Lu
A1 Pengcheng Li
A1 Yun Ling
A1 Zhong Yang
A1 Huiru Tang
A1 Leming Shi
A1 Li Jin
A1 Edward C. Holmes
A1 Chen Ding
A1 Tong-Yu Zhu
A1 Yong-Zhen Zhang
YR 2020
UL http://medrxiv.org/content/early/2020/06/22/2020.06.19.20134379.abstract
AB COVID-19 is characterised by dysregulated immune responses, metabolic dysfunction and adverse effects on the function of multiple organs. To understand how host responses contribute to COVID-19 pathophysiology, we used a multi-omics approach to identify molecular markers in peripheral blood and plasma samples that distinguish COVID-19 patients experiencing a range of disease severities. A large number of expressed genes, proteins, metabolites and extracellular RNAs (exRNAs) were identified that exhibited strong associations with various clinical parameters. Multiple sets of tissue-specific proteins and exRNAs varied significantly in both mild and severe patients, indicative of multi-organ damage. The continuous activation of IFN-I signalling and neutrophils, as well as a high level of inflammatory cytokines, were observed in severe disease patients. In contrast, COVID-19 in mild patients was characterised by robust T cell responses. Finally, we show that some of expressed genes, proteins and exRNAs can be used as biomarkers to predict the clinical outcomes of SARS-CoV-2 infection. These data refine our understanding of the pathophysiology and clinical progress of COVID-19 and will help guide future studies in this area.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Natural Science Foundation of China (grants 81861138003, 31930001, 32041004 and 81672057) and the Special National Project on investigation of basic resources of China (grant 2019FY101400), and Shanghai Municipal Science and Technology Major Project (Grant No. 2017SHZDZX01). E.C.H. is supported by an ARC Australian Laureate Fellowship (FL170100022).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human samples included in the present study were obtained after approval of the research by the Shanghai Public Health Clinical Center Ethics Committee (YJ-2020-S018-02), together with the written informed consent from each patient.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets produced in this study are available in the following databases: RNA-Seq and exRNA-Seq Data: NODE OEP000868; Raw mass spectrometry data: iProX IPX 0002186001